Cantargia (OMX: CANTA)

Currency in SEK

Last close As at 09/06/2023

SEK4.64

0.03 (0.65%)

Market capitalisation

SEK775m

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Increasing understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Goran Forsberg

    CEO

Balance Sheet

Forecast net cash (SEKm)

119.4

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (21.0) (29.4) (67.7)
Relative (21.7) (29.5) (68.5)
52 week high/low SEK14.1/SEK3.0

Financials

Cantargia is developing antibodies against IL1RAP. Data from its Phase IIa CANFOUR trial, investigating nadunolimab in first-line NSCLC and pancreatic ductal adenocarcinoma (PDAC), support the hypothesis that nadunolimab has a synergistic benefit with chemotherapy. The company is now preparing for a Phase II/III trial in metastatic PDAC in collaboration with PanCAN and a follow-on randomised study in NSCLC. Additionally, in Q123, the first patient was dosed in the Phase II part of the TRIFOUR study investigating nadunolimab for the treatment of triple-negative breast cancer. A second programme, CAN10, is being developed for the treatment of myocarditis and systemic sclerosis and the company intends to initiate Phase I trials in H123. Cantargia had a cash and short-term investment position of SEK426.7m at end-FY22.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2021A 0.0 (366.8) (366.5) (365.80) N/A N/A
2022A 0.0 (377.9) (371.8) (290.43) N/A N/A
2023E 0.0 (302.1) (306.6) (183.58) N/A N/A
2024E 0.0 (286.9) (292.6) (175.20) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free